Literature DB >> 28523180

Primary atypical carcinoid tumor of the mediastinum: a very rare finding.

Luigi Ventura1, Letizia Gnetti2, Enrico Maria Silini2, Guido Rindi3, Paolo Carbognani1, Michele Rusca1, Luca Ampollini1.   

Abstract

Primary neuroendocrine tumors (NETs) of the mediastinum are very rare. Prognosis is usually poor despite treatment options. We present the case of a primary atypical carcinoid tumor of the mediastinum successfully treated by multimodal approach. A 50-year-old man presented for asthenia, dyspnea, and substernal sense of weight for two weeks. A chest-CT scan revealed a tumor mass of 107×55×95 mm3 localized in the anterosuperior mediastinum compressing both brachiocephalic veins, the superior vena cava, the pericardium, and lungs. A FDG-PET demonstrated high FDG uptake only in the mediastinal mass; no metastases were seen. CT-guided needle biopsy revealed a NET; cells were immunoreactive for synaptophysin; Ki67 was 20%. After neoadjuvant chemotherapy, the chest CT-scan showed a significant reduction of the tumor. A surgical excision was proposed. The tumor was radically removed along with a partial resection of the vena cava and reconstruction with a bovine pericardium patch. The patient underwent 25 sessions of adjuvant radiotherapy. Microscopically the tumor showed clusters of medium-sized cells, eosinophilic cytoplasm with nuclear pleomorphism and small nucleoli, arranged in trabeculae, nests and lobules. No thymic tissue was found. Immunohistochemically the tumor cells were positive for CD117, synaptophysin, chromogranin, CD56, cytokeratin pool, epithelial membrane antigen (EMA), and negative for thyroid transcription factor-1 (TTF1), leukocyte common antigen (LCA), fibroblast-activation protein (FAP), prostate-specific antigen (PSA), P63, CD5 and CD99. Mitoses were found to be 8/10 HPF. The Ki67 was 10%. A diagnosis of primary NET of the mediastinum, intermediate grade (G2), atypical carcinoid according to WHO 2015, was formulated. Even in case of primary NE mediastinal tumor, a multimodal approach could lead to long-term survival.

Entities:  

Keywords:  Mediastinum; atypical carcinoid; multimodal treatment; neuroendocrine tumor (NET); surgery

Year:  2017        PMID: 28523180      PMCID: PMC5418266          DOI: 10.21037/jtd.2017.03.154

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  15 in total

Review 1.  Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.

Authors:  M E Caplin; E Baudin; P Ferolla; P Filosso; M Garcia-Yuste; E Lim; K Oberg; G Pelosi; A Perren; R E Rossi; W D Travis
Journal:  Ann Oncol       Date:  2015-02-02       Impact factor: 32.976

2.  Malignant neuroendocrine tumor presenting a huge mediastinal mass controlled with radiation therapy.

Authors:  M Furuta; K Hayakawa; S Kato; N Mitsuhashi; T Nakajima; H Niibe
Journal:  Lung Cancer       Date:  1998-10       Impact factor: 5.705

3.  Prognostic model of survival for typical bronchial carcinoid tumours: analysis of 1109 patients on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours Working Group.

Authors:  Pier Luigi Filosso; Francesco Guerrera; Andrea Evangelista; Stefan Welter; Pascal Thomas; Paula Moreno Casado; Erino Angelo Rendina; Federico Venuta; Luca Ampollini; Alessandro Brunelli; Franco Stella; Mario Nosotti; Federico Raveglia; Valentina Larocca; Ottavio Rena; Stefano Margaritora; Francesco Ardissone; William D Travis; Inderpal Sarkaria; Dariusz Sagan
Journal:  Eur J Cardiothorac Surg       Date:  2015-01-05       Impact factor: 4.191

4.  Giant neuroendocrine tumour localized to the thoracoabdomen.

Authors:  Oleg Pikin; Dmitry Sidorov; Ali Amiraliev; Olga Kirsanova
Journal:  Eur J Cardiothorac Surg       Date:  2013-03-03       Impact factor: 4.191

Review 5.  Neuroendocrine neoplasms of the mediastinum.

Authors:  S Suster; C A Moran
Journal:  Am J Clin Pathol       Date:  2001-06       Impact factor: 2.493

Review 6.  Primary neuroendocrine carcinomas of the mediastinum: review of current criteria for histopathologic diagnosis and classification.

Authors:  Cesar A Moran
Journal:  Semin Diagn Pathol       Date:  2005-08       Impact factor: 3.464

Review 7.  Tumors of the mediastinum.

Authors:  Beau V Duwe; Daniel H Sterman; Ali I Musani
Journal:  Chest       Date:  2005-10       Impact factor: 9.410

8.  Primary neuroendocrine carcinoma of the mediastinum.

Authors:  Füruzan Kacar; Ibrahim Meteoglu; Serdar Sen; Edi Levi
Journal:  Pathol Oncol Res       Date:  2003-01-06       Impact factor: 3.201

9.  Neuroendocrine carcinoma in a mediastinal teratoma as a rare variant of somatic-type malignancy.

Authors:  Inga-Marie Schaefer; Patrick Zardo; Stefan Freermann; Alexander Marx; Philipp Ströbel; Stefan Fischer
Journal:  Virchows Arch       Date:  2013-08-25       Impact factor: 4.064

10.  Differential diagnostic value of CD5 and CD117 expression in thoracic tumors: a large scale study of 1465 non-small cell lung cancer cases.

Authors:  Mark Kriegsmann; Thomas Muley; Alexander Harms; Luca Tavernar; Torsten Goldmann; Hendrik Dienemann; Esther Herpel; Arne Warth
Journal:  Diagn Pathol       Date:  2015-12-08       Impact factor: 2.644

View more
  3 in total

Review 1.  Classification of pulmonary neuroendocrine tumors: new insights.

Authors:  Giuseppe Pelosi; Angelica Sonzogni; Sergio Harari; Adriana Albini; Enrica Bresaola; Caterina Marchiò; Federica Massa; Luisella Righi; Gaia Gatti; Nikolaos Papanikolaou; Namrata Vijayvergia; Fiorella Calabrese; Mauro Papotti
Journal:  Transl Lung Cancer Res       Date:  2017-10

2.  Atypical carcinoid: A rare finding of a man with mediastinal mass: A case report.

Authors:  Wei-Xia Xuan; Jin-Jin Li; Yu-Jie Shi; Xiao-Ju Zhang
Journal:  Mol Clin Oncol       Date:  2020-02-19

3.  Locally advanced primary mediastinal atypical carcinoid successfully resected after neoadjuvant treatment: A case report.

Authors:  Alberto Testori; Vittorio Perfetti; Camilla De Carlo; Paola Bossi; Marco Alloisio; Giuseppe Mangiameli
Journal:  Thorac Cancer       Date:  2021-08-03       Impact factor: 3.500

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.